Fusilev (levoleucovorin) Drug Information: Description, User Reviews, Drug Side Effects, Interactions

Pill Identifier Search

May 27, 2012

Fusilev

Colon Cancer »

Colon cancer facts

Colorectal cancer is a malignant tumor arising from the inner wall of the large intestine.
Colorectal cancer is the third leading cause of cancer in males and fourth in females in the U.S.
Risk factors for colorectal cancer include heredity, colon polyps, and long-standing ulcerative colitis.
Most colorectal cancers develop from polyps. Removal of colon polyps can prevent colorectal cancer.
Colon polyps and early cancer can have no symptoms. Therefore regular screening is important.
Diagnosis of colorectal cancer can be made by barium enema or by colonoscopy with biopsy confirmation of cancer tissue.
Treatment of colorectal cancer depends on the location, size, and extent of cancer spread, as well as the age and health of the patient.
Surgery is the most c...

Read the Colon Cancer article »

Fusilev

Breast Cancer Slideshow Pictures

Pancreatic Cancer Slideshow Pictures

Skin Cancer Slideshow Pictures

font size

Fusilev®
(levoleucovorin)

DRUG DESCRIPTION

Levoleucovorin is the levo isomeric form of racemic d,l-leucovorin, present as the calcium salt. Levoleucovorin is the pharmacologically active isomer of leucovorin [(6-S)-leucovorin].

Fusilev for Injection and Fusilev Injection contain levoleucovorin calcium, which is one of several active, chemically reduced derivatives of folic acid. It is useful as antidote to the inhibition of dihydrofolate reductase by methotrexate. This compound has the chemical designation calcium (6S)-N-{4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6pteridinyl)methyl] amino]benzoyl}-L-glutamate pentahydrate. The molecular weight is 601.6 and the structural formula is:

Fusilev® (levoleucovorin) Structural Formula Illustration

Its molecular formula is: C₂₀H₂₁CaN₇O₇• 5H₂O.

Fusilev for Injection is supplied as a sterile lyophilized powder consisting of 64 mg levoleucovorin calcium pentahydrate (equivalent to 50 mg levoleucovorin) and 50 mg mannitol per 50 mg vial. Sodium hydroxide and/or hydrocholoric acid are used to adjust the pH during manufacture. It is intended for intravenous administration after reconstitution with 5.3 mL of sterile 0.9% Sodium Chloride Injection, USP [See DOSAGE AND ADMINISTRATION]

Fusilev Injection is supplied as a sterile solution of either 175 mg levoleucovorin in 17.5 mL or 250 mg levoleucovorin in 25 mL. Each mL contains levoleucovorin calcium pentahydrate equivalent to 10 mg levoleucovorin and 8.3 mg sodium chloride. Sodium hydroxide is used for pH adjustment to pH 8.0 (6.5 to 8.5).

Last reviewed on RxList: 6/6/2011
This monograph has been modified to include the generic and brand name in many instances.